Immune oncology and neuroendocrine tumors

Ann Oncol. 2017 Sep 1;28(9):2322-2323. doi: 10.1093/annonc/mdx260.

Authors

A Chauhan¹, L Anthony¹

Affiliation

¹ Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, USA.

PMID: 28505259
DOI: 10.1093/annonc/mdx260

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Female
Humans
Male
Middle Aged
Neoplasms, Unknown Primary / drug therapy
Neoplasms, Unknown Primary / immunology
Neuroendocrine Tumors / drug therapy*
Neuroendocrine Tumors / immunology*
Nivolumab
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / immunology*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Nivolumab
pembrolizumab